Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings
Aim: We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell engager (BiTE®) immune therapy mediating T-cell killing of tumor cells in patients with advanced castration-resistant prostate cancer. Patients & methods: We assessed once-daily subcutaneous (SC) pasotuxi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 2021
|
| In: |
Immunotherapy
Year: 2021, Jahrgang: 13, Heft: 2, Pages: 125-141 |
| ISSN: | 1750-7448 |
| DOI: | 10.2217/imt-2020-0256 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.2217/imt-2020-0256 Verlag, kostenfrei, Volltext: https://www.futuremedicine.com/doi/10.2217/imt-2020-0256 
|
| Verfasserangaben: | Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich, Ruth Seggewiss-Bernhardt, Barbara Deschler-Baier, Manik Chatterjee, Maria-Elisabeth Goebeler, Kurt Miller, Maria de Santis, Wolfgang Loidl, Christian Dittrich, Andreas Buck, Constantin Lapa, Annette Thurner, Sabine Wittemer-Rump, Gökben Koca, Oliver Boix, Wolf-Dietrich Döcke, Ricarda Finnern, Helena Kusi, Antoinette Ajavon-Hartmann, Sabine Stienen, Cyrus Michael Sayehli, Bülent Polat & Ralf C Bargou |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 188759227X | ||
| 003 | DE-627 | ||
| 005 | 20250116225930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240502s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/imt-2020-0256 |2 doi | |
| 035 | |a (DE-627)188759227X | ||
| 035 | |a (DE-599)KXP188759227X | ||
| 035 | |a (OCoLC)1443669920 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hummel, Horst-Dieter |d 1977- |e VerfasserIn |0 (DE-588)142512435 |0 (DE-627)636717976 |0 (DE-576)331353539 |4 aut | |
| 245 | 1 | 0 | |a Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer |b phase I, dose-escalation study findings |c Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich, Ruth Seggewiss-Bernhardt, Barbara Deschler-Baier, Manik Chatterjee, Maria-Elisabeth Goebeler, Kurt Miller, Maria de Santis, Wolfgang Loidl, Christian Dittrich, Andreas Buck, Constantin Lapa, Annette Thurner, Sabine Wittemer-Rump, Gökben Koca, Oliver Boix, Wolf-Dietrich Döcke, Ricarda Finnern, Helena Kusi, Antoinette Ajavon-Hartmann, Sabine Stienen, Cyrus Michael Sayehli, Bülent Polat & Ralf C Bargou |
| 264 | 1 | |c February 2021 | |
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 11. November 2020 | ||
| 500 | |a Gesehen am 02.05.2024 | ||
| 520 | |a Aim: We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell engager (BiTE®) immune therapy mediating T-cell killing of tumor cells in patients with advanced castration-resistant prostate cancer. Patients & methods: We assessed once-daily subcutaneous (SC) pasotuxizumab. All SC patients developed antidrug antibodies; therefore, continuous intravenous (cIV) infusion was assessed. Results: A total of 47 patients received pasotuxizumab (SC: n = 31, 0.5-172 μg/d; cIV: n = 16, 5-80 μg/d). The SC maximum tolerated dose was 172.0 μg/d. A sponsor change stopped the cIV cohort early; maximum tolerated dose was not determined. PSA responders occurred (>50% PSA decline: SC, n = 9; cIV, n = 3), including two long-term responders. Conclusion: Data support pasotuxizumab safety in advanced castration-resistant prostate cancer and represent evidence of BiTE monotherapy efficacy in solid tumors. - - Clinical trial registration: NCT01723475 (ClinicalTrials.gov) | ||
| 650 | 4 | |a AMG 212 | |
| 650 | 4 | |a BAY 2010112 | |
| 650 | 4 | |a bispecific T-cell engager (BiTE®) immune therapy | |
| 650 | 4 | |a pasotuxizumab | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a PSMA | |
| 700 | 1 | |a Kufer, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grüllich, Carsten |d 1965- |e VerfasserIn |0 (DE-588)14101914X |0 (DE-627)624500985 |0 (DE-576)321797981 |4 aut | |
| 700 | 1 | |a Seggewiss-Bernhardt, Ruth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Deschler-Baier, Barbara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chatterjee, Manik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goebeler, Maria-Elisabeth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Miller, Kurt |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Santis, Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loidl, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dittrich, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Buck, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Lapa, Constantin Frederik Victor |d 1982- |e VerfasserIn |0 (DE-588)1011355892 |0 (DE-627)65846180X |0 (DE-576)341412856 |4 aut | |
| 700 | 1 | |a Thurner, Annette |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wittemer-Rump, Sabine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Koca, Gökben |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boix, Oliver |e VerfasserIn |4 aut | |
| 700 | 1 | |a Döcke, Wolf-Dietrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Finnern, Ricarda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kusi, Helena |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ajavon-Hartmann, Antoinette |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stienen, Sabine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sayehli, Cyrus Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Polat, Bülent |e VerfasserIn |4 aut | |
| 700 | 1 | |8 2\p |a Bargou, Ralf C. |d 1961- |e VerfasserIn |0 (DE-588)112553737X |0 (DE-627)880192747 |0 (DE-576)483457450 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunotherapy |d London : Taylor & Francis, 2009 |g 13(2021), 2 vom: Nov., Seite 125-141 |h Online-Ressource |w (DE-627)600591891 |w (DE-600)2495964-9 |w (DE-576)398101108 |x 1750-7448 |7 nnas |a Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer phase I, dose-escalation study findings |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:2 |g month:11 |g pages:125-141 |g extent:17 |a Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer phase I, dose-escalation study findings |
| 856 | 4 | 0 | |u https://doi.org/10.2217/imt-2020-0256 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.futuremedicine.com/doi/10.2217/imt-2020-0256 |x Verlag |z kostenfrei |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20240502 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 14101914X |a Grüllich, Carsten |m 14101914X:Grüllich, Carsten |d 50000 |e 50000PG14101914X |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN188759227X |e 4519858437 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Hummel, Horst-Dieter","family":"Hummel","role":"aut","given":"Horst-Dieter"},{"display":"Kufer, Peter","given":"Peter","role":"aut","family":"Kufer"},{"display":"Grüllich, Carsten","role":"aut","given":"Carsten","family":"Grüllich"},{"given":"Ruth","role":"aut","family":"Seggewiss-Bernhardt","display":"Seggewiss-Bernhardt, Ruth"},{"display":"Deschler-Baier, Barbara","family":"Deschler-Baier","role":"aut","given":"Barbara"},{"display":"Chatterjee, Manik","given":"Manik","role":"aut","family":"Chatterjee"},{"role":"aut","given":"Maria-Elisabeth","family":"Goebeler","display":"Goebeler, Maria-Elisabeth"},{"display":"Miller, Kurt","given":"Kurt","role":"aut","family":"Miller"},{"family":"de Santis","given":"Maria","role":"aut","display":"de Santis, Maria"},{"display":"Loidl, Wolfgang","family":"Loidl","role":"aut","given":"Wolfgang"},{"display":"Dittrich, Christian","family":"Dittrich","role":"aut","given":"Christian"},{"role":"aut","given":"Andreas","family":"Buck","display":"Buck, Andreas"},{"display":"Lapa, Constantin Frederik Victor","role":"aut","given":"Constantin Frederik Victor","family":"Lapa"},{"display":"Thurner, Annette","given":"Annette","role":"aut","family":"Thurner"},{"display":"Wittemer-Rump, Sabine","role":"aut","given":"Sabine","family":"Wittemer-Rump"},{"role":"aut","given":"Gökben","family":"Koca","display":"Koca, Gökben"},{"display":"Boix, Oliver","given":"Oliver","role":"aut","family":"Boix"},{"display":"Döcke, Wolf-Dietrich","family":"Döcke","given":"Wolf-Dietrich","role":"aut"},{"given":"Ricarda","role":"aut","family":"Finnern","display":"Finnern, Ricarda"},{"display":"Kusi, Helena","family":"Kusi","role":"aut","given":"Helena"},{"given":"Antoinette","role":"aut","family":"Ajavon-Hartmann","display":"Ajavon-Hartmann, Antoinette"},{"given":"Sabine","role":"aut","family":"Stienen","display":"Stienen, Sabine"},{"display":"Sayehli, Cyrus Michael","family":"Sayehli","role":"aut","given":"Cyrus Michael"},{"display":"Polat, Bülent","role":"aut","given":"Bülent","family":"Polat"},{"family":"Bargou","given":"Ralf C.","role":"aut","display":"Bargou, Ralf C."}],"title":[{"title_sort":"Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer","subtitle":"phase I, dose-escalation study findings","title":"Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer"}],"language":["eng"],"physDesc":[{"extent":"17 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.2217/imt-2020-0256"],"eki":["188759227X"]},"origin":[{"dateIssuedDisp":"February 2021","dateIssuedKey":"2021"}],"name":{"displayForm":["Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich, Ruth Seggewiss-Bernhardt, Barbara Deschler-Baier, Manik Chatterjee, Maria-Elisabeth Goebeler, Kurt Miller, Maria de Santis, Wolfgang Loidl, Christian Dittrich, Andreas Buck, Constantin Lapa, Annette Thurner, Sabine Wittemer-Rump, Gökben Koca, Oliver Boix, Wolf-Dietrich Döcke, Ricarda Finnern, Helena Kusi, Antoinette Ajavon-Hartmann, Sabine Stienen, Cyrus Michael Sayehli, Bülent Polat & Ralf C Bargou"]},"recId":"188759227X","note":["Online veröffentlicht: 11. November 2020","Gesehen am 02.05.2024"],"relHost":[{"origin":[{"publisher":"Taylor & Francis ; Future Medicine Ltd","dateIssuedKey":"2009","dateIssuedDisp":"2009-","publisherPlace":"London ; London"}],"id":{"eki":["600591891"],"zdb":["2495964-9"],"issn":["1750-7448"]},"part":{"pages":"125-141","volume":"13","extent":"17","text":"13(2021), 2 vom: Nov., Seite 125-141","issue":"2","year":"2021"},"recId":"600591891","disp":"Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer phase I, dose-escalation study findingsImmunotherapy","title":[{"title":"Immunotherapy","title_sort":"Immunotherapy"}],"note":["Gesehen am 28.05.2024"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.2009 -"],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}]}]} | ||
| SRT | |a HUMMELHORSPASOTUXIZU2021 | ||